Discover CME, tools, and guideline-focused education to improve your knowledge - and patient outcomes.
Non-CF Bronchiectasis: How Radiologists Can Drive Better Outcomes
Robert D. Suh, MD
Lea Azour, MD
Ashwin Basavaraj, MD
Acromegaly Care: Individualized Diagnosis and Management Strategies
July 13, 2025
San Francisco, California
What’s New In Glaucoma?
Paul Petrakos, DO, MS
Justin Schweitzer, OD, FAAO
I. Paul Singh, MD
Sarah H. Van Tassel, MD
New Strategies for Individualizing Treatment in DME
Luis A. Gonzalez, MD, MPH
Jeremiah Brown Jr., MD, MS, FASRS
Trial in Progress: Phase 3 MoonRISe-3 Study
SunRISe-1: 1-Year Durability and Patient-Reported Outcomes Results
First Results From Cohort 4 of the SunRISe-1 Trial
Treatment Advances in Generalized Myasthenia Gravis: Addressing the Nuances of its Underlying Immunopathology
Vera Bril, MD
Nicholas J. Silvestri, MD
Hans Katzberg, MD
Chairperson's Perspective: Innovative Approaches to IBS-C: Personalized Treatment for Better Outcomes
Darren Brenner, MD
Expert Perspectives From AUA 2025: Contextualizing the Evolving Landscape of Bladder Cancer
Neal Shore, MD, FACS
Sarah Psutka, MD, MS
Revolutionizing Diagnostic Precision: AI-Driven Approaches in Digital Pathology and HER2 Expression
Marilyn Yuanxin Ma Bui, MD, PhD
Anne Vincent-Salomon, MD
Precision Medicine for gMG: Tailoring Treatments Based on Patient Profiles
Living with gMG: Navigating Personal, Professional, and Mental Health Challenges
A Scientific Look at FcRn Antagonists: Mechanisms of Action Explained
Diagnostic Advances in gMG: Effective Tools and Techniques
Traditional MG Treatments: Balancing Benefits, Risks, and Side Effect Management
Treatment Advances in Generalized Myasthenia Gravis: Clinical and Laboratory Criteria for Diagnosis and Optimal Treatment Selection
Jonathan Strober, MD
Managing Side Effects in FcRn Therapy: Best Practices for gMG
New Frontiers in MG: How FcRn Antagonists Are Changing MG Therapy
Autoantibodies Explained: Anti-AChR, Anti-MuSK, and Their Diagnostic Role
Preventing Myasthenic Crisis: Early Signs and Critical Interventions
Collaborative Insights to Solve the Puzzle of Bladder Cancer
Daniel P. Petrylak, MD
Elizabeth R. Plimack, MD, MS, FASCO
Evan Y. Yu, MD
Chairperson’s Perspective: Treating At-Risk MASH: What Are You Waiting For?
Mazen Noureddin, MD, MHSc
What’s New in Glaucoma Topical Therapies?
New Solutions for Optimizing IOP Control: A Case-Based Approach
What’s New With 3D Visualization in Glaucoma Surgery?
Loading...
We're glad to see you're enjoying Prova Education… but how about a more personalized experience?
Press cancel to remain on Prova Education. Press the link below or the continue button to keep going.